Bone Biologics Corporation (BBLG) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Bone Biologics Corporation (BBLG) closed at USD 0.41 on 2026-10-14, a change of -81.1 % over the past year, with a market capitalization of USD 1.07M.

Bone Biologics Corporation recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Bone Biologics Corporation key figures

Previous close

USD 0.41 (2026-10-14)

1-year change

-81.1 %

Market cap

USD 1.07M

Enterprise value

USD -2.96M

P/E ratio (trailing)

-0.31

P/E ratio (forward)

-0.58

EPS (trailing)

-1.27

EPS (forward)

-0.67

PEG ratio

n/a

Price to book

0.18

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

0.17

Employees

2

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Bone Biologics Corporation

Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein in the United States. Its lead product is NELL-1/DBM medical device, an osteopromotive recombinant protein, which provides target specific control over bone regeneration. The company also develops NB1, a NELL-1/DBM fusion device for use in lumbar spinal fusion, as well as spine implants, non-union trauma cases, and osteoporosis applications. It serves spine surgeons and patients with a skeletal bone defect or bone-related condition in their spine. The company has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion by local administration, osteoporosis, and trauma applications. Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Bone Biologics Corporation and compare it with other stocks.